Verve Therapeutics, Inc. (VERV) has a consensus analyst rating of Hold, based on 13 analysts covering the stock. Of those, 4 recommend buying, 8 recommend holding, and 1 recommend selling.
The analyst consensus price target for VERV is $15.00, representing a +34.8% upside from the current price of $11.13. Price targets range from a low of $15.00 to a high of $15.00.
